Kontaktujte nás | Jazyk: čeština English
dc.title | Transcript expression and genetic variability analysis of caspases in breast carcinomas suggests CASP9 as the most interesting target | en |
dc.contributor.author | Brynychová, Veronika | |
dc.contributor.author | Hlaváč, Viktor | |
dc.contributor.author | Ehrlichová, Marie | |
dc.contributor.author | Václavíková, Radka | |
dc.contributor.author | Němcová-Fürstová, Vlasta | |
dc.contributor.author | Pecha, Václav | |
dc.contributor.author | Trnková, Markéta | |
dc.contributor.author | Mrhalová, Marcela | |
dc.contributor.author | Kodet, Roman | |
dc.contributor.author | Vrána, David | |
dc.contributor.author | Gatěk, Jiří | |
dc.contributor.author | Bendová, Marie | |
dc.contributor.author | Vernerová, Zdeňka | |
dc.contributor.author | Kovář, Jan | |
dc.contributor.author | Souček, Pavel | |
dc.relation.ispartof | Clinical Chemistry and Laboratory Medicine | |
dc.identifier.issn | 1434-6621 Scopus Sources, Sherpa/RoMEO, JCR | |
dc.date.issued | 2017 | |
utb.relation.volume | 55 | |
utb.relation.issue | 1 | |
dc.citation.spage | 111 | |
dc.citation.epage | 122 | |
dc.type | article | |
dc.language.iso | en | |
dc.publisher | Walter de Gruyter GmbH | |
dc.identifier.doi | 10.1515/cclm-2016-0271 | |
dc.subject | alternative splicing | en |
dc.subject | breast carcinoma | en |
dc.subject | caspases | en |
dc.subject | prognosis | en |
dc.subject | transcript | en |
dc.description.abstract | Background: Apoptosis plays a critical role in cancer cell survival and tumor development. We provide a hypothesis- generating screen for further research by exploring the expression profile and genetic variability of caspases (2, 3, 7, 8, 9, and 10) in breast carcinoma patients. This study addressed isoform-specific caspase transcript expression and genetic variability in regulatory sequences of caspases 2 and 9. Methods: Gene expression profiling was performed by quantitative real-time PCR in tumor and paired non-malignant tissues of two independent groups of patients. Genetic variability was determined by high resolution melting, allelic discrimination, and sequencing analysis in tumor and peripheral blood lymphocyte DNA of the patients. Results: CASP3 A+ B and S isoforms were over-expressed in tumors of both patient groups. The CASP9 transcript was down-regulated in tumors of both groups of patients and significantly associated with expression of hormonal receptors and with the presence of rs4645978-rs2020903rs4646034 haplotype in the CASP9 gene. Patients with a low intratumoral CASP9A/B isoform expression ratio (predicted to shift equilibrium towards anti-apoptotic isoform) subsequently treated with adjuvant chemotherapy had a significantly shorter disease-free survival than those with the high ratio (p = 0.04). Inheritance of CC genotype of rs2020903 in CASP9 was associated with progesterone receptor expression in tumors (p = 0.003). Conclusions: Genetic variability in CASP9 and expression of its splicing variants present targets for further study. | en |
utb.faculty | Faculty of Humanities | |
dc.identifier.uri | http://hdl.handle.net/10563/1006847 | |
utb.identifier.obdid | 43877897 | |
utb.identifier.scopus | 2-s2.0-84998694303 | |
utb.identifier.wok | 000388930700021 | |
utb.identifier.pubmed | 27327132 | |
utb.identifier.coden | CCLMF | |
utb.source | j-wok | |
dc.date.accessioned | 2017-02-28T15:11:32Z | |
dc.date.available | 2017-02-28T15:11:32Z | |
dc.description.sponsorship | CU Grant Agency [1444313]; MH CZ - DRO (National Institute of Public Health - NIPH) project [75010330]; Internal Grant Agency of the Czech Ministry of Health [14055-3] | |
utb.contributor.internalauthor | Gatěk, Jiří | |
utb.fulltext.affiliation | Veronika Brynychova, Viktor Hlavac, Marie Ehrlichova, Radka Vaclavikova, Vlasta NemcovaFurstova, Vaclav Pecha, Marketa Trnkova, Marcela Mrhalova, Roman Kodet, David Vrana, Jiri Gatek, Marie Bendova, Zdenka Vernerova, Jan Kovar, Pavel Soucek * * Corresponding author: Pavel Soucek, Toxicogenomics Unit, Department of Toxicology and Safety, National Institute of Public Health, Srobarova 48, 100 42, Prague 10, Czech Republic, Phone: +420 2 6708 2711, Fax: +420 2 6731 1236, E-mail: [email protected]; www.szu.cz Veronika Brynychova and Viktor Hlavac: Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic; and Third Faculty of Medicine, Charles University in Prague, Prague, Czech Republic Marie Ehrlichova and Radka Vaclavikova: Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic Vlasta Nemcova-Furstova and Jan Kovar: Division of Cell and Molecular Biology, Third Faculty of Medicine, Charles University in Prague, Prague, Czech Republic Vaclav Pecha: Institute for the Care for Mother and Child, Prague, Czech Republic Marketa Trnkova: Biolab Ltd. Praha, Prague, Czech Republic Marcela Mrhalova and Roman Kodet: Department of Pathology and Molecular Medicine, Second Faculty of Medicine, Charles University in Prague and Motol University Hospital, Prague, Czech Republic David Vrana: Toxicogenomics Unit, National Institute of Public Health, Prague, Czech Republic; and Department of Oncology, Palacky University Medical School and Teaching Hospital, Olomouc, Czech Republic Jiri Gatek: Department of Surgery, Hospital Atlas, Zlin, Czech Republic; and University of Tomas Bata in Zlin, Zlin, Czech Republic Marie Bendova: Department of Gynaecology and Obstetrics, Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic Zdenka Vernerova: Department of Pathology, Faculty Hospital Kralovske Vinohrady, Prague, Czech Republic | |
utb.fulltext.dates | Received April 5, 2016 accepted May 17, 2016 previously published online June 21, 2016 |